The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Open accessAbstract
BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood samples, 17 antibody or cellular assays met prespecified criteria, of which 6 were chosen for primary analysis to determine the roles of T-cell, IgG antibody, and IgA antibody responses in the modulation of infection risk. Assays were performed on samples from 41 vaccinees who became infected and 205 uninfected vaccinees, obtained 2 weeks after final immunization, to evaluate whether immune-response variables predicted HIV-1 infection through 42 months of follow-up. RESULTS: Of six primary variables, two correlated significantly with infection risk: the binding of IgG antibodies to variable regions 1 and 2 (V1V2) of HIV-1 envelope proteins (Env) correlated inversely with the rate of HIV-1 infection (estimated odds ratio, 0.57 per 1-SD increase; P=0.02; q=0.08), and the binding of plasma IgA antibodies to Env correlated directly with the rate of infection (estimated odds ratio, 1.54 per 1-SD increase; P=0.03; q=0.08). Neither low levels of V1V2 antibodies nor high levels of Env-specific IgA antibodies were associated with higher rates of infection than were found in the placebo group. Secondary analyses suggested that Env-specific IgA antibodies may mitigate the effects of potentially protective antibodies. CONCLUSIONS: This immune-correlates study generated the hypotheses that V1V2 antibodies may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies may have mitigated the effects of protective antibodies. Vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Self-citationCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Self-citationProfound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., et al. (2011) · Nature · doi:10.1038/nature10003 · Cited by 988
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationVaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465
Self-citationPreserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys
Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., Yang, Z.-Y., Chakrabarti, B., Rao, S. S., Schmitz, J. E., et al. (2006) · Science · doi:10.1126/science.1124226 · Cited by 372
Self-citation
Cited by
HIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationDeeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
Self-citationTowards an HIV cure: a global scientific strategy
The International AIDS Society Scientific Working Group on HIV Cure (2012) · Nature Reviews Immunology · doi:10.1038/nri3262 · Cited by 554
Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies
Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J. F., Halper-Stromberg, A., Gnanapragasam, P. N. P., Spencer, D. I. R., Seaman, M. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217207109 · Cited by 550
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Yates, N. L., Liao, H.-X., Fong, Y., deCamp, A., Vandergrift, N. A., Williams, W. T., Alam, S. M., Ferrari, G., Yang, Z.-Y., Seaton, K. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007730 · Cited by 450
Self-citationPathophysiology of T follicular helper cells in humans and mice
Ueno, H., Banchereau, J., & Vinuesa, C. G. (2015) · Nature Immunology · doi:10.1038/ni.3054 · Cited by 439
Cirelli, K. M., Carnathan, D. G., Nogal, B., Martin, J. T., Rodriguez, O. L., Upadhyay, A. A., Enemuo, C. A., Gebru, E. H., Choe, Y., Viviano, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.012 · Cited by 433
Delany, I., Rappuoli, R., & De Gregorio, E. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 420
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Rolland, M., Edlefsen, P. T., Larsen, B. B., Tovanabutra, S., Sanders-Buell, E., Hertz, T., deCamp, A. C., Carrico, C., Menis, S., Magaret, C. A., et al. (2012) · Nature · doi:10.1038/nature11519 · Cited by 417
Self-citationSex differences in vaccine-induced humoral immunity
Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H., & Alter, G. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0726-5 · Cited by 410
Chung, A. W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.-S., Schoen, M. K., Rolland, M., Suscovich, T. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007736 · Cited by 406
Self-citationTomaras, G. D., Ferrari, G., Shen, X., Alam, S. M., Liao, H.-X., Pollara, J., Bonsignori, M., Moody, M. A., Fong, Y., Chen, X., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301456110 · Cited by 394
Self-citationBunker, J. J., & Bendelac, A. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.011 · Cited by 388
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Liao, H.-X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 377
Self-citationBonsignori, M., Pollara, J., Moody, M. A., Alpert, M. D., Chen, X., Hwang, K.-K., Gilbert, P. B., Huang, Y., Gurley, T. C., Kozink, D. M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01023-12 · Cited by 375
Self-citationNatural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity
Ackerman, M. E., Crispin, M., Yu, X., Baruah, K., Boesch, A. W., Harvey, D. J., Dugast, A.-S., Heizen, E. L., Ercan, A., Choi, I., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65708 · Cited by 358
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Chung, A. W., Kumar, M. P., Arnold, K. B., Yu, W. H., Schoen, M. K., Dunphy, L. J., Suscovich, T. J., Frahm, N., Linde, C., Mahan, A. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.027 · Cited by 352
Self-citationStrategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Self-citationEnhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Lu, C.-L., Murakowski, D. K., Bournazos, S., Schoofs, T., Sarkar, D., Halper-Stromberg, A., Horwitz, J. A., Nogueira, L., Golijanin, J., Gazumyan, A., et al. (2016) · Science · doi:10.1126/science.aaf1279 · Cited by 347
Barouch, D. H., Stephenson, K. E., Borducchi, E. N., Smith, K., Stanley, K., McNally, A. G., Liu, J., Abbink, P., Maxfield, L. F., Seaman, M. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.061 · Cited by 342
Self-citationBarouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L., Nkolola, J. P., Borducchi, E. N., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31364-3 · Cited by 336
Self-citationThe use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 310
Pauthner, M., Havenar-Daughton, C., Sok, D., Nkolola, J. P., Bastidas, R., Boopathy, A. V., Carnathan, D. G., Chandrashekar, A., Cirelli, K. M., Cottrell, C. A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.05.007 · Cited by 305
Self-citationProtective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
Barouch, D. H., Alter, G., Broge, T., Linde, C., Ackerman, M. E., Brown, E. P., Borducchi, E. N., Smith, K. M., Nkolola, J. P., Liu, J., et al. (2015) · Science · doi:10.1126/science.aab3886 · Cited by 297
Defeating AIDS—advancing global health
Piot, P., Abdool Karim, S. S., Hecht, R., Legido-Quigley, H., Buse, K., Stover, J., Resch, S., Ryckman, T., Møgedal, S., Dybul, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60658-4 · Cited by 293
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
COMPASS identifies T-cell subsets correlated with clinical outcomes
Lin, L., Finak, G., Ushey, K., Seshadri, C., Hawn, T. R., Frahm, N., Scriba, T. J., Mahomed, H., Hanekom, W., Bart, P.-A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3187 · Cited by 278
Self-citationNabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Elimination of HIV-1-infected cells by broadly neutralizing antibodies
Bruel, T., Guivel-Benhassine, F., Amraoui, S., Malbec, M., Richard, L., Bourdic, K., Donahue, D. A., Lorin, V., Casartelli, N., Noël, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms10844 · Cited by 271
Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo
Kato, Y., Abbott, R. K., Freeman, B. L., Haupt, S., Groschel, B., Silva, M., Menis, S., Irvine, D. J., Schief, W. R., & Crotty, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.001 · Cited by 269
Zolla-Pazner, S., deCamp, A., Gilbert, P. B., Williams, C., Yates, N. L., Williams, W. T., Howington, R., Fong, Y., Morris, D. E., Soderberg, K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087572 · Cited by 267
Self-citationVeillette, M., Désormeaux, A., Medjahed, H., Gharsallah, N.-E., Coutu, M., Baalwa, J., Guan, Y., Lewis, G., Ferrari, G., Hahn, B. H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03230-13 · Cited by 265
Self-citationIrrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil, M., Beileke, S., Schäfer, S., Zhong, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade2798 · Cited by 264
Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
Cipponi, A., Mercier, M., Seremet, T., Baurain, J.-F., Théate, I., van den Oord, J., Stas, M., Boon, T., Coulie, P. G., & van Baren, N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1377 · Cited by 259
Bégin, P., Callum, J., Jamula, E., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01488-2 · Cited by 258
Self-citationPolyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control
Ackerman, M. E., Mikhailova, A., Brown, E. P., Dowell, K. G., Walker, B. D., Bailey-Kellogg, C., Suscovich, T. J., & Alter, G. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005315 · Cited by 258
Nonhuman primate models of human viral infections
Estes, J. D., Wong, S. W., & Brenchley, J. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0005-7 · Cited by 255
Saphire, E. O., Schendel, S. L., Fusco, M. L., Gangavarapu, K., Gunn, B. M., Wec, A. Z., Halfmann, P. J., Brannan, J. M., Herbert, A. S., Qiu, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.033 · Cited by 212
“Although non-neutralizing antibodies can offer in vivo protection from Ebola and other viruses (Haynes et al., 2012; Henry Dunand et al., 2016; Horwitz et al., 2017; Lewis et al., 2015; Olinger et al., 2012; Wilson et al., 2000), neutralization is often the primary selector of mAbs for in vivo evaluation.”
Duerr, A., Huang, Y., Buchbinder, S., Coombs, R. W., Sanchez, J., del Rio, C., Casapia, M., Santiago, S., Gilbert, P., Corey, L., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis342 · Cited by 210
Self-citationCytotoxic CD4 T Cells—Friend or Foe during Viral Infection?
Juno, J. A., van Bockel, D., Kent, S. J., Kelleher, A. D., Zaunders, J. J., & Munier, C. M. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00019 · Cited by 195
Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu522 · Cited by 181
“The gp70-CaseA V1V2 scaffold antigen was provided by Drs Liao and Haynes [35, 37].”
BackgroundMethodSelf-citationCurrent advances in the development of SARS-CoV-2 vaccines
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.52569 · Cited by 164
Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Self-citationSivro, A., Schuetz, A., Sheward, D., Joag, V., Yegorov, S., Liebenberg, L. J., Yende-Zuma, N., Stalker, A., Mwatelah, R. S., Selhorst, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6354 · Cited by 94
Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors
Campion, S. L., Brodie, T. M., Fischer, W., Korber, B. T., Rossetti, A., Goonetilleke, N., McMichael, A. J., & Sallusto, F. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130555 · Cited by 84
Golding, H., Khurana, S., & Zaitseva, M. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028902 · Cited by 67
“No strong HIV-neutralizing antibodies or cellmediated immunity were detected in uninfected vaccine recipients (Haynes et al. 2012; Yates et al. 2014; Zolla-Pazner et al. 2014).”
BackgroundGardner, M. R., Fetzer, I., Kattenhorn, L. M., Davis-Gardner, M. E., Zhou, A. S., Alfant, B., Weber, J. A., Kondur, H. R., Martinez-Navio, J. M., Fuchs, S. P., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.004 · Cited by 60
Shangguan, S., Ehrenberg, P. K., Geretz, A., Yum, L., Kundu, G., May, K., Fourati, S., Nganou-Makamdop, K., Williams, L. D., Sawant, S., et al. (2021) · eLife · doi:10.7554/elife.69577 · Cited by 26
Self-citationDennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., Kunz, E. L., Zhang, R., Vandergrift, N., Permar, S., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01031-14 · Cited by 18
Self-citation
Metadata
- Authors
- Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., Liao, H.-X., DeVico, A. L., Lewis, G. K., Williams, C., Pinter, A., Fong, Y., Janes, H., DeCamp, A., Huang, Y., Rao, M., Billings, E., Karasavvas, N., Robb, M. L., Ngauy, V., de Souza, M. S., Paris, R., Ferrari, G., Bailer, R. T., Soderberg, K. A., Andrews, C., Berman, P. W., Frahm, N., De Rosa, S. C., Alpert, M. D., Yates, N. L., Shen, X., Koup, R. A., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N. L., & Kim, J. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-04-05
- Volume
- 366
- Issue
- 14
- Pages
- 1275-1286
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2143421242
- Cited by
- 1,808
- References
- 29
- FWCI
- 87.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.